This challenge targets the hypothesis: **NLRP3 Inhibition (H7): Downstream Inflammatory Reversal** **Hypothesis Summary:** Pharmacological NLRP3 inhibition via MCC950 breaks the lipid-inflammasome feedback loop that perpetuates microglial activation. Does not require upstream lipid normalization; directly tests whether established inflammation is reversible. Most clinically actionable surviving hypothesis with tractable medicinal chemistry and established translational pathway. **Falsifiable Predictions:** 1. Pharmacological modulation of NLRP3/NLRP3 (NLRP3 inflammasome) will alter neurodegeneration markers in validated models by ≥20% 2. Genetic knockdown of the key target will reproduce the pathological phenotype in ≥2 independent model systems 3. Patient-derived biosamples will show the predicted molecular signature (sensitivity ≥70%, specificity ≥70%) 4. Mechanistic intervention at the proposed node will rescue neuronal viability in vitro by ≥30% **Bounty Tier:** $128,000 USD (composite score 0.780) **Challenge Type:** Open — any team may submit experimental evidence supporting or refuting this hypothesis **Success Criteria:** Peer-reviewed evidence demonstrating mechanistic validation of ≥2 of the 4 predictions, with independent replication.